ClinicalTrials.gg
CompletedNCT01469234Updated Mar 11, 2015Results posted

A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)

A Phase 4 interventional study of loratadine and fexofenadine in Rhinitis, sponsored by Bayer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-11.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the onset of action of two commercially available over-the-counter antihistamines (Loratadine and

Fexofenadine) in a model of seasonal allergic rhinitis (SAR). Participants undergo sensitization exposures to Mountain Cedar (juniperus ashei) pollen in a Biogenics Research Chamber; those who demonstrate an adequate allergic response determined by the Major Symptom Complex (MSC) score will then receive drug.

02

Conditions studied

  • Rhinitis

Browse trials for

03

In context

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

This study's enrollment of 255 is above the median of 80 across 187 interventional studies indexed under Rhinitis.

Browse Rhinitis studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants of child bearing potential must demonstrate a negative

urine pregnancy test at Screening (Visit 1) and Visit 4 (prior to randomization) and agree to use (and/or have their partner use) 2 acceptable methods of beginning at the Screening visit and throughout the study.

  • Willing to stop use of current decongestant and allergy medications at the start of the (Visit 1) and during the trial.
  • Documented history or participant-reported history of seasonal allergic rhinitis caused by mountain cedar pollen within the last 2 years and documented or participant-reported symptoms over at least the last 2 mountain cedar allergy seasons.
  • Documented skin testing (prick with wheal ≥ 4 mm larger than the diluent) within the last 1 year to mountain cedar pollen present.
  • Capable of reading English.
  • (BMI) \<35.

Exclusion criteria

Exclusion Criteria:

  • Any significant medical condition which, in the judgment of the investigator, is a to the use of loratadine, fexofenadine or might interfere with the trial. These may include thyroid disease (e.g., hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease, elevated intraocular pressure, prostatic hypertrophy.
  • Have started allergen immunotherapy within 1 month preceding enrollment or participants starting allergen immunotherapy or anticipating immunotherapy dose change during the trial. Xolair (omalizumab) may not be used within 4 years prior to trial participation.
  • Known allergy or intolerance to loratadine, desloratadine, or fexofenadine.
  • History of rhinitis medicamentosa.
  • Use of systemic (oral, rectal, injectable), topical (up to 1% topical hydrocortisone is permitted), or nasal in the last 30 days or current or expected use of disallowed medications as listed in the protocol.
  • Asthma, with the exception of mild intermittent asthma.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    loratadine

    Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.

    Drug: loratadine · Drug: placebo to fexofenadine

  • Experimental
    fexofenadine

    Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.

    Drug: fexofenadine · Drug: placebo to loratadine

  • Placebo comparator
    placebo

    Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.

    Drug: placebo to loratadine · Drug: placebo to fexofenadine

Interventions

  • loratadine, one 10 mg tablet, orally

    Also known as: SCH 029851

  • fexofenadine, one 180 mg tablet, orally

  • Drugplacebo to loratadine

    one tablet, orally

  • Drugplacebo to fexofenadine

    one tablet, orally

06

What researchers measure

Primary outcomes

  1. Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)

    The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

Secondary outcomes

  1. Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point

    The individual symptom score for Runny Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  2. Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point

    The individual symptom score for Itchy Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  3. Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point

    The individual symptom score for Sneezing was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  4. Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point

    The individual symptom score for Water Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  5. Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point

    The individual symptom score for Itchy Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  6. Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point

    The individual symptom score for Nasal Congestion was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

  7. Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point

    The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

    Time frame: From time of sensitization (time 0) to end of visit (~8 hours)

07

Results

Posted Mar 22, 2013

Participant flow

Participant flow — Overall Study
MilestoneLoratadineFexofenadinePlacebo
Started858585
Completed858585
Not completed000

Outcome measures

PrimaryMean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)

The MSC Score is calculated as the sum of 5 individual symptom scores for Runny Nose, Itchy Nose, Sneezing, Watery Eyes, and Itchy Eyes. Each individual symptom is rated on a 5-point scale of severity: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The total MSC score ranges from 0 - 25. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Major Symptom Complex (MSC) Score by Post-Treatment Evaluation Time Point (From 180 Minutes to 300 Minutes)
units on a scaleLoratadineFexofenadinePlacebo
180 minutes (n=85, n=85, n=85)7.4 ± 4.516.7 ± 4.868.5 ± 5.07
195 minutes (n=85, n=85, n=85)7.5 ± 4.846.7 ± 4.878.9 ± 5.31
210 minutes (n=85, n=85, n=85)7.3 ± 4.736.5 ± 4.878.7 ± 5.28
225 minutes (n=85, n=85, n=85)7.4 ± 4.636.5 ± 4.708.5 ± 5.36
240 minutes (n=84, n=85, n=85)7.4 ± 4.766.5 ± 4.438.3 ± 5.38
255 minutes (n=85, n=85, n=85)7.1 ± 4.786.3 ± 4.478.4 ± 5.51
270 minutes (n=85, n=85, n=85)7.0 ± 4.676.4 ± 4.508.4 ± 5.56
285 minutes (n=85, n=85, n=85)7.3 ± 4.526.9 ± 4.768.7 ± 5.76
300 minutes (n=84, n=85, n=85)7.1 ± 4.546.5 ± 4.658.4 ± 5.58
SecondaryMean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point

The individual symptom score for Runny Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Runny Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Score for Runny Nose by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes3.4 ± 0.773.2 ± 0.783.3 ± 0.89
15 minutes3.1 ± 0.853.0 ± 0.913.0 ± 1.09
30 minutes3.0 ± 0.952.9 ± 0.992.9 ± 1.14
45 minutes2.8 ± 0.992.6 ± 1.052.8 ± 1.15
60 minutes2.7 ± 1.062.3 ± 1.022.7 ± 1.20
75 minutes2.6 ± 1.062.2 ± 1.082.6 ± 1.20
90 minutes2.4 ± 1.042.1 ± 1.082.4 ± 1.28
105 minutes2.4 ± 1.102.1 ± 1.032.5 ± 1.16
120 minutes2.1 ± 1.072.0 ± 1.002.3 ± 1.18
135 minutes2.2 ± 1.122.0 ± 1.072.4 ± 1.19
150 minutes2.3 ± 1.102.0 ± 1.072.4 ± 1.20
165 minutes2.2 ± 1.071.8 ± 1.142.3 ± 1.18
180 minutes2.1 ± 1.201.9 ± 1.202.3 ± 1.17
195 minutes2.1 ± 1.271.9 ± 1.212.4 ± 1.20
210 minutes2.0 ± 1.231.8 ± 1.222.3 ± 1.24
225 minutes2.1 ± 1.221.8 ± 1.242.3 ± 1.19
240 minutes2.0 ± 1.231.8 ± 1.192.2 ± 1.20
255 minutes2.0 ± 1.301.7 ± 1.152.3 ± 1.28
270 minutes1.9 ± 1.301.8 ± 1.102.3 ± 1.35
285 minutes2.1 ± 1.241.9 ± 1.152.3 ± 1.31
300 minutes2.0 ± 1.261.8 ± 1.142.3 ± 1.28
315 minutes2.1 ± 1.251.8 ± 1.172.4 ± 1.30
330 minutes2.2 ± 1.261.8 ± 1.182.3 ± 1.31
345 minutes2.1 ± 1.271.8 ± 1.172.4 ± 1.32
360 minutes2.1 ± 1.291.9 ± 1.232.3 ± 1.33
SecondaryMean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point

The individual symptom score for Itchy Nose was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Nose symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Score for Itchy Nose by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes3.3 ± 0.743.3 ± 0.733.4 ± 0.77
15 minutes3.1 ± 0.843.2 ± 0.813.1 ± 0.93
30 minutes2.8 ± 0.972.8 ± 0.972.8 ± 0.99
45 minutes2.7 ± 1.022.6 ± 0.962.8 ± 1.04
60 minutes2.6 ± 1.092.4 ± 1.052.6 ± 1.07
75 minutes2.4 ± 1.162.3 ± 1.142.5 ± 1.19
90 minutes2.3 ± 1.102.1 ± 1.072.4 ± 1.17
105 minutes2.2 ± 1.082.1 ± 1.102.4 ± 1.10
120 minutes1.9 ± 1.141.8 ± 1.122.1 ± 1.20
135 minutes2.0 ± 1.121.8 ± 1.172.2 ± 1.22
150 minutes2.1 ± 1.061.8 ± 1.192.2 ± 1.18
165 minutes2.0 ± 1.091.7 ± 1.222.2 ± 1.14
180 minutes2.0 ± 1.161.8 ± 1.252.2 ± 1.12
195 minutes1.9 ± 1.231.7 ± 1.222.2 ± 1.20
210 minutes2.0 ± 1.251.7 ± 1.282.2 ± 1.20
225 minutes1.9 ± 1.181.7 ± 1.272.2 ± 1.25
240 minutes1.9 ± 1.141.7 ± 1.242.2 ± 1.24
255 minutes1.8 ± 1.241.7 ± 1.212.2 ± 1.30
270 minutes1.9 ± 1.181.7 ± 1.252.1 ± 1.31
285 minutes1.9 ± 1.171.8 ± 1.222.2 ± 1.29
300 minutes1.8 ± 1.191.8 ± 1.202.1 ± 1.32
315 minutes1.8 ± 1.261.8 ± 1.222.2 ± 1.38
330 minutes1.8 ± 1.161.7 ± 1.252.1 ± 1.31
345 minutes1.9 ± 1.231.7 ± 1.292.2 ± 1.36
360 minutes1.8 ± 1.221.8 ± 1.322.2 ± 1.38
SecondaryMean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point

The individual symptom score for Sneezing was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Sneezing symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Scores for Sneezing by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes (n=85, n=85, n=85)1.3 ± 1.371.2 ± 1.361.5 ± 1.40
15 minutes (n=85, n=85, n=85)1.2 ± 1.311.2 ± 1.391.3 ± 1.37
30 minutes (n=85, n=85, n=85)1.2 ± 1.341.1 ± 1.321.2 ± 1.38
45 minutes (n=85, n=85, n=85)1.0 ± 1.290.9 ± 1.221.3 ± 1.39
60 minutes (n=85, n=85, n=85)1.1 ± 1.210.7 ± 1.121.2 ± 1.36
75 minutes (n=85, n=85, n=85)1.0 ± 1.250.8 ± 1.161.1 ± 1.39
90 minutes (n=85, n=85, n=85)0.7 ± 1.120.6 ± 1.071.0 ± 1.37
105 minutes (n=85, n=85, n=85)0.8 ± 1.160.6 ± 1.071.1 ± 1.43
120 minutes (n=85, n=85, n=85)0.5 ± 0.880.5 ± 1.040.9 ± 1.28
135 minutes (n=85, n=85, n=85)0.8 ± 1.130.7 ± 1.201.2 ± 1.48
150 minutes (n=85, n=85, n=85)0.9 ± 1.220.6 ± 1.141.1 ± 1.32
165 minutes (n=85, n=85, n=85)0.8 ± 1.110.5 ± 1.030.9 ± 1.32
180 minutes (n=85, n=85, n=85)0.7 ± 1.080.6 ± 1.110.9 ± 1.30
195 minutes (n=85, n=85, n=85)0.8 ± 1.190.6 ± 1.091.0 ± 1.38
210 minutes (n=85, n=85, n=85)0.7 ± 1.070.5 ± 1.031.0 ± 1.31
225 minutes (n=85, n=85, n=85)0.7 ± 1.040.6 ± 0.930.9 ± 1.33
240 minutes (n=85, n=85, n=85)0.7 ± 1.090.5 ± 1.040.9 ± 1.29
255 minutes (n=85, n=85, n=85)0.6 ± 1.150.4 ± 0.861.0 ± 1.41
270 minutes (n=85, n=85, n=85)0.6 ± 1.130.5 ± 1.001.0 ± 1.40
285 minutes (n=85, n=85, n=85)0.8 ± 1.080.6 ± 1.071.1 ± 1.42
300 minutes (n=84, n=85, n=85)0.7 ± 1.020.5 ± 0.950.9 ± 1.34
315 minutes (n=84, n=85, n=85)0.7 ± 1.100.4 ± 0.941.1 ± 1.40
330 minutes (n=85, n=85, n=85)0.7 ± 1.020.6 ± 1.031.0 ± 1.38
345 minutes (n=84, n=85, n=85)0.7 ± 1.090.6 ± 0.991.0 ± 1.33
360 minutes (n=85, n=85, n=85)0.6 ± 1.120.6 ± 1.091.0 ± 1.38
SecondaryMean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point

The individual symptom score for Water Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Watery Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Scores for Watery Eyes by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes2.7 ± 1.122.8 ± 1.052.7 ± 1.02
15 minutes2.4 ± 1.172.6 ± 1.102.4 ± 1.15
30 minutes2.2 ± 1.232.3 ± 1.172.1 ± 1.25
45 minutes1.9 ± 1.222.0 ± 1.192.0 ± 1.18
60 minutes1.8 ± 1.211.9 ± 1.161.9 ± 1.12
75 minutes1.7 ± 1.211.8 ± 1.191.6 ± 1.11
90 minutes1.5 ± 1.291.6 ± 1.231.5 ± 1.18
105 minutes1.5 ± 1.221.6 ± 1.131.5 ± 1.19
120 minutes1.3 ± 1.151.3 ± 1.091.4 ± 1.18
135 minutes1.2 ± 1.111.3 ± 1.111.4 ± 1.29
150 minutes1.2 ± 1.121.2 ± 1.191.4 ± 1.20
165 minutes1.2 ± 1.141.2 ± 1.141.4 ± 1.20
180 minutes1.2 ± 1.071.1 ± 1.121.3 ± 1.16
195 minutes1.2 ± 1.151.2 ± 1.191.5 ± 1.21
210 minutes1.2 ± 1.141.1 ± 1.131.4 ± 1.27
225 minutes1.2 ± 1.131.1 ± 1.161.4 ± 1.25
240 minutes1.2 ± 1.161.1 ± 1.101.4 ± 1.24
255 minutes1.2 ± 1.121.1 ± 1.131.4 ± 1.26
270 minutes1.2 ± 1.131.1 ± 1.091.4 ± 1.21
285 minutes1.2 ± 1.081.2 ± 1.131.4 ± 1.27
300 minutes1.2 ± 1.021.1 ± 1.101.3 ± 1.32
315 minutes1.2 ± 1.091.2 ± 1.131.4 ± 1.33
330 minutes1.3 ± 1.141.2 ± 1.151.4 ± 1.32
345 minutes1.2 ± 1.151.2 ± 1.191.4 ± 1.32
360 minutes1.2 ± 1.201.3 ± 1.171.4 ± 1.34
SecondaryMean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point

The individual symptom score for Itchy Eyes was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Eyes symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Scores for Itchy Eyes by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes (n=85, n=85, n=85)3.0 ± 0.933.2 ± 0.873.1 ± 1.08
15 minutes (n=85, n=85, n=84)2.6 ± 1.103.0 ± 1.022.8 ± 1.15
30 minutes (n=85, n=85, n=85)2.4 ± 1.122.7 ± 1.172.4 ± 1.20
45 minutes (n=85, n=85, n=85)2.2 ± 1.142.3 ± 1.172.4 ± 1.24
60 minutes (n=85, n=85, n=85)1.9 ± 1.142.1 ± 1.142.2 ± 1.23
75 minutes (n=85, n=85, n=85)1.9 ± 1.142.0 ± 1.201.9 ± 1.25
90 minutes (n=85, n=85, n=85)1.8 ± 1.211.8 ± 1.171.9 ± 1.28
105 minutes (n=85, n=85, n=85)1.8 ± 1.181.8 ± 1.151.8 ± 1.29
120 minutes (n=85, n=85, n=85)1.6 ± 1.191.6 ± 1.141.7 ± 1.30
135 minutes (n=85, n=85, n=85)1.5 ± 1.141.5 ± 1.131.7 ± 1.28
150 minutes (n=85, n=85, n=85)1.5 ± 1.061.4 ± 1.201.6 ± 1.32
165 minutes (n=85, n=85, n=85)1.5 ± 1.111.4 ± 1.241.7 ± 1.28
180 minutes (n=85, n=85, n=85)1.4 ± 1.111.4 ± 1.181.7 ± 1.23
195 minutes (n=85, n=85, n=85)1.5 ± 1.151.4 ± 1.191.8 ± 1.30
210 minutes (n=85, n=85, n=85)1.4 ± 1.121.4 ± 1.211.7 ± 1.26
225 minutes (n=85, n=85, n=85)1.5 ± 1.151.4 ± 1.191.7 ± 1.28
240 minutes (n=84, n=85, n=85)1.6 ± 1.191.4 ± 1.111.7 ± 1.29
255 minutes (n=85, n=85, n=85)1.4 ± 1.131.4 ± 1.181.6 ± 1.31
270 minutes (n=85, n=85, n=85)1.4 ± 1.091.4 ± 1.151.6 ± 1.30
285 minutes (n=85, n=85, n=85)1.3 ± 1.161.4 ± 1.171.7 ± 1.42
300 minutes (n=85, n=85, n=85)1.4 ± 1.191.4 ± 1.181.7 ± 1.33
315 minutes (n=85, n=85, n=85)1.4 ± 1.191.4 ± 1.241.7 ± 1.36
330 minutes (n=85, n=85, n=85)1.5 ± 1.211.4 ± 1.241.6 ± 1.38
345 minutes (n=85, n=85, n=85)1.4 ± 1.231.4 ± 1.271.8 ± 1.38
360 minutes (n=85, n=85, n=85)1.5 ± 1.341.4 ± 1.251.7 ± 1.37
SecondaryMean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point

The individual symptom score for Nasal Congestion was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Nasal Congestion symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Scores for Nasal Congestion by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes (n=85, n=85, n=85)3.4 ± 0.813.2 ± 0.883.4 ± 0.76
15 minutes (n=85, n=85, n=85)2.5 ± 1.202.2 ± 1.252.7 ± 1.19
30 minutes (n=85, n=85, n=85)1.6 ± 1.331.5 ± 1.192.0 ± 1.26
45 minutes (n=85, n=85, n=85)2.5 ± 1.162.1 ± 1.212.6 ± 1.22
60 minutes (n=85, n=85, n=85)1.6 ± 1.291.4 ± 1.201.8 ± 1.34
75 minutes (n=85, n=85, n=85)2.4 ± 1.252.1 ± 1.212.6 ± 1.24
90 minutes (n=85, n=85, n=85)1.6 ± 1.271.3 ± 1.191.8 ± 1.34
105 minutes (n=85, n=85, n=85)2.4 ± 1.242.1 ± 1.202.6 ± 1.24
120 minutes (n=85, n=85, n=85)1.5 ± 1.261.4 ± 1.171.8 ± 1.31
135 minutes (n=85, n=85, n=85)2.4 ± 1.242.1 ± 1.192.6 ± 1.26
150 minutes (n=85, n=85, n=85)1.5 ± 1.311.3 ± 1.191.8 ± 1.31
165 minutes (n=85, n=85, n=85)2.4 ± 1.262.0 ± 1.142.5 ± 1.33
180 minutes (n=85, n=85, n=85)1.4 ± 1.221.3 ± 1.221.8 ± 1.39
195 minutes (n=85, n=85, n=85)2.5 ± 1.212.0 ± 1.152.6 ± 1.25
210 minutes (n=85, n=85, n=85)1.5 ± 1.311.3 ± 1.201.8 ± 1.34
225 minutes (n=85, n=85, n=85)2.4 ± 1.212.0 ± 1.242.6 ± 1.28
240 minutes (n=85, n=85, n=85)1.5 ± 1.291.4 ± 1.211.8 ± 1.32
255 minutes (n=85, n=85, n=84)2.4 ± 1.262.0 ± 1.192.6 ± 1.30
270 minutes (n=85, n=85, n=84)1.6 ± 1.291.3 ± 1.221.8 ± 1.46
285 minutes (n=85, n=85, n=85)2.4 ± 1.312.1 ± 1.192.6 ± 1.34
300 minutes (n=85, n=85, n=85)1.5 ± 1.311.3 ± 1.251.8 ± 1.43
315 minutes (n=85, n=85, n=85)2.4 ± 1.292.1 ± 1.192.5 ± 1.39
330 minutes (n=85, n=85, n=85)1.5 ± 1.311.3 ± 1.241.8 ± 1.47
345 minutes (n=85, n=85, n=85)2.4 ± 1.282.0 ± 1.242.5 ± 1.33
360 minutes (n=85, n=85, n=85)1.5 ± 1.311.4 ± 1.311.9 ± 1.51
SecondaryMean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point

The individual symptom score for Itchy Mouth/Throat/Ears was rated on a 5-point scale of severity using the following scale: 0 = None (No symptoms), 1 = MILD (Symptom is present, but easily tolerated), 2 = MODERATE (Awareness of symptoms, bothersome, but tolerable), 3 = SEVERE (Definite awareness of symptoms, difficult to tolerate but does not interfere with activities), 4 = VERY SEVERE (Difficult to tolerate and interferes with the activities of daily living). The Itchy Mouth/Throat/Ears symptom score ranges from 0 - 5. Increasing scores are associated with increasing severity.

Time frame:
From time of sensitization (time 0) to end of visit (~8 hours)
Reported as:
Mean · units on a scale
Mean Individual Symptom Scores for Itchy Mouth/Throat/Ears by Post-Treatment Evaluation Time Point
units on a scaleLoratadineFexofenadinePlacebo
0 minutes (n=85, n=85, n=85)3.0 ± 1.083.0 ± 1.052.9 ± 1.17
15 minutes (n=85, n=85, n=85)3.2 ± 1.053.0 ± 1.063.0 ± 1.09
30 minutes (n=85, n=85, n=85)2.6 ± 1.192.8 ± 1.172.6 ± 1.27
45 minutes (n=85, n=85, n=85)3.0 ± 1.112.8 ± 1.092.8 ± 1.06
60 minutes (n=85, n=85, n=85)2.3 ± 1.292.6 ± 1.272.4 ± 1.25
75 minutes (n=85, n=85, n=85)2.8 ± 1.162.6 ± 1.162.8 ± 1.12
90 minutes (n=85, n=85, n=85)2.0 ± 1.222.3 ± 1.162.3 ± 1.25
105 minutes (n=85, n=85, n=85)2.7 ± 1.192.4 ± 1.172.6 ± 1.14
120 minutes (n=85, n=85, n=85)1.9 ± 1.242.0 ± 1.152.1 ± 1.31
135 minutes (n=85, n=85, n=85)2.6 ± 1.202.3 ± 1.242.5 ± 1.24
150 minutes (n=85, n=85, n=85)1.8 ± 1.211.8 ± 1.171.9 ± 1.32
165 minutes (n=85, n=85, n=85)2.5 ± 1.172.2 ± 1.212.4 ± 1.29
180 minutes (n=85, n=85, n=85)1.7 ± 1.201.7 ± 1.211.8 ± 1.29
195 minutes (n=85, n=85, n=85)2.4 ± 1.252.1 ± 1.172.4 ± 1.26
210 minutes (n=85, n=85, n=85)1.6 ± 1.211.7 ± 1.121.9 ± 1.28
225 minutes (n=85, n=85, n=85)2.3 ± 1.132.0 ± 1.202.3 ± 1.25
240 minutes (n=85, n=85, n=85)1.5 ± 1.181.5 ± 1.151.7 ± 1.31
255 minutes (n=85, n=85, n=84)2.3 ± 1.192.0 ± 1.222.4 ± 1.28
270 minutes (n=85, n=85, n=85)1.5 ± 1.201.6 ± 1.161.7 ± 1.29
285 minutes (n=85, n=85, n=85)2.4 ± 1.162.0 ± 1.262.4 ± 1.31
300 minutes (n=85, n=85, n=85)1.5 ± 1.141.4 ± 1.211.8 ± 1.32
315 minutes (n=85, n=85, n=85)2.4 ± 1.182.0 ± 1.232.4 ± 1.30
330 minutes (n=85, n=85, n=85)1.4 ± 1.191.4 ± 1.221.7 ± 1.23
345 minutes (n=85, n=85, n=85)2.3 ± 1.202.0 ± 1.252.5 ± 1.29
360 minutes (n=85, n=85, n=85)1.4 ± 1.171.3 ± 1.211.7 ± 1.27

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Loratadine—0/85 (0%)0/85 (0%)
Fexofenadine—0/85 (0%)0/85 (0%)
Placebo—0/85 (0%)0/85 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)LoratadineFexofenadinePlaceboTotal
Mean41.5 ± 13.5243.1 ± 12.2140.6 ± 12.5641.7 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)LoratadineFexofenadinePlaceboTotal
Female515353157
Male34323298
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2013, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2011
First posted
Nov 10, 2011
Start
Oct 2011
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Mar 22, 2013
Last update
Mar 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01469234
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 10, 2011
Start date
Oct 2011
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Mar 22, 2013
Last update
Mar 11, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Loratadine · Fexofenadine

Start the discussion